Dilated Cardiomyopathy

Dilated cardiomyopathy is a disorder of the heart muscle that involves the widening and/or dilation of the left ventricle of the heart along with left ventricular or biventricular systolic dysfunction. These uncommon cardiovascular problems like dilated cardiomyopathy pose particular challenges in the realm of drug discovery and development, Protheragen as a specialized research service provider can offer comprehensive solutions for therapy research.

Overview of Dilated Cardiomyopathy

Myocardial contractile dysfunction, alongside ventricular dilation, characterizes dilated cardiomyopathy. It is one of the most common forms of cardiovascular disease (CVD) associated with heart failure. The characteristic feature of dilated cardiomyopathy is the impairment of systolic function and the dilation of the left or both ventricles devoid of identifiable causative factors. One epidemiological study cites the prevalence of dilated cardiomyopathy as 36.5 in 100,000 individuals and the male-to-female ratio was 3 to 4.

Fig.1 Illustrates immune responses in dilated cardiomyopathy. (Harding, D., et al., 2023)

Pathogenesis of Dilated Cardiomyopathy

Dilated cardiomyopathy may result from various factors including genetic mutations, chronic alcoholism, certain chemotherapeutic drugs, and sometimes even pregnancy. Roughly 40% of the familial cases of dilated cardiomyopathy show pathological changes that follow mainly an autosomal dominant mode of inheritance. While dilated cardiomyopathy is linked to over fifty genes, the most important ones are certainly TTN, LMNA, TNNT2, and MYH7.

Fig.2 Overview of dilated cardiomyopathy. (Harding, D., et al., 2023)

Therapeutics Development for Dilated Cardiomyopathy

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.

Our Services

Leveraging our advanced infrastructure, we can assist you in the research of cardiovascular diseases by offering professional personnel. So that researchers have all the requisite tools and services for their investigation, we offer diagnostic development, therapeutic development, and the development of disease models. We seek to augment preclinical study efforts by assisting in the discovery of biomarkers and therapy exploration through extensive support.

Therapeutic Development Services

Diverse Platforms

• Small Molecule Drug Development
• Gene Therapy Development
• Therapeutic Peptide Development

• Cell Therapy Development
• Therapeutic Antibody Development
• Therapeutic Protein Development

Animal Model Development for Dilated Cardiomyopathy

For effective study and therapy development of dilated cardiomyopathy, developing appropriate animal models is essential. In our firm, we create custom animal models of dilated cardiomyopathy that are both inducible and genetically engineered to meet the particular requirements of the client's research.

Genetically Engineered Model

These models include transgenic or knockout animals which are created through genetic engineering to observe the impacts of certain gene alterations related to dilated cardiomyopathy.

Optional models:

• Lmna mutation model
• Nexn mutation model
• Tbx5 mutation model
• Other models

Induced Animal Model

These models utilize external agents like toxins and viral infections to replicate the pathology of dilated cardiomyopathy and observe its progression and potential therapy strategies.

Optional models:

• Doxorubicin-induced model
• Cardiac myosin-induced model
• CVB3 infection model
• Other models

Aside from providing drug discovery related services, Protheragen also provides comprehensive preclinical services such as pharmacokinetics and drug safety evaluation. Our unwavering focus on quality and its impact on outcomes and deliverables drives efficiency. With us, you can expedite your research efforts to develop new therapies for dilated cardiomyopathy. Reach out to us for further details on how we can help you.

Reference

• Harding, Daniel et al. "Dilated cardiomyopathy and chronic cardiac inflammation: Pathogenesis, diagnosis and therapy." Journal of internal medicine 293.1 (2023): 23-47.